Status:

COMPLETED

Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults

Lead Sponsor:

Tonix Pharmaceuticals, Inc.

Conditions:

Healthy Adults

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

Very low dose (VLD) cyclobenzaprine at bedtime has shown promise as a treatment for fibromyalgia, but the chemistry of cyclobenzaprine requires new formulation technology for bedtime use. The present ...

Eligibility Criteria

Inclusion

  • Healthy adults
  • Male or female
  • 18-65 years old
  • Non-smoker
  • BMI \> 18.5 and \< 30.0
  • With medically acceptable form of contraception (female only)
  • With signed informed consent

Exclusion

  • Any clinically significant abnormality including ECG abnormalities or vital sign abnormalities (systolic blood pressure \< 90 or \> 140 mmHg,
  • Diastolic blood pressure lower \< 50 or \> 90 mmHg, or heart rate \< 50 or \> 100 BPM)
  • Any abnormal laboratory test (including positivity for Hep B, Hep C, HIV, and
  • Hemoglobin \< 128 g/L (males) or \< 115 g/L (females) and hematocrit \< 0.37 L/L (males) or \< 0.32 L/L (females))
  • History of alcohol or drug abuse or dependence within 1 year and/or positive drug, cotinine, or alcohol tests
  • Use of any drug (within 30 days), supplement, or food (within 14 days) known to induce or inhibit hepatic drug metabolism prior to study medication
  • Positive pregnancy test, breastfeeding or lactating
  • Use of medication other than hormonal contraceptives or topical products, including OTC, natural health products, MAO inhibitors
  • Participation in an investigational study within 30 days prior to dosing
  • Donation of plasma (within 7 days), or donation or loss of blood of 50-499 mL (within 30 days), or of \> 499 mL (within 56 days) prior to dosing.

Key Trial Info

Start Date :

June 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2014

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT01889173

Start Date

June 1 2013

End Date

March 1 2014

Last Update

September 26 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

PharmaNet, Inc.

Québec, Quebec, Canada, G1P 0A2